Stocks Comparison
Neogenomics vs UL Solutions: revenue, profit, margins and growth compared
Neogenomics brought in $727.3M of revenue in fiscal 2025, UL Solutions $3.1B in fiscal 2025. Revenue changed by +10.1% at Neogenomics and +6.4% at UL Solutions on the year before, so Neogenomics grew faster. Neogenomics kept -14.9% of its revenue as net profit, UL Solutions 10.6%. Free cash flow was -$21.8M at Neogenomics and $403M at UL Solutions.
Side by side, latest fiscal year
| NEO | ULS | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $727.3M | $3.1B |
| Revenue growth | +10.1% | +6.4% |
| Net income | -$108M | $325M |
| Net margin | -14.9% | 10.6% |
| Free cash flow | -$21.8M | $403M |
| Free cash flow margin | -3.0% | 13.2% |
| Earnings per share (diluted) | n/a | $1.60 |
| Cash | $159.6M | $295M |
| Debt | $341.9M | $491M |
| Price to earnings | n/a | 41.3 |
| Market value | $2.5B | $13.3B |
| Dividend yield | n/a | 0.79% |
| Rank by revenue in sector | #170 of 523 · Health care | #85 of 523 · Health care |
Over the years
Questions about Neogenomics and UL Solutions
Which is bigger by revenue, Neogenomics or UL Solutions?
UL Solutions is bigger by revenue: $3.1B in fiscal 2025, against $727.3M for Neogenomics in fiscal 2025.
Which keeps more of its revenue as profit, Neogenomics or UL Solutions?
Neogenomics had a net margin of -14.9% in fiscal 2025; UL Solutions had 10.6% in fiscal 2025.
Which grew revenue faster, Neogenomics or UL Solutions?
In their latest fiscal years revenue changed by +10.1% at Neogenomics and +6.4% at UL Solutions.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.